Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis
CONCLUSIONS: This meta-analysis indicates that most pharmacotherapies decreased the frequency of binge-eating and vomiting episodes, body weight, and depressive symptoms in BN patients, but the efficacy was not significant. In each drug the efficacy is different, treating different aspects, different symptoms to improve the clinical performance of bulimia nervosa.PMID:38042827 | DOI:10.1186/s40360-023-00713-7 (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - December 2, 2023 Category: Drugs & Pharmacology Authors: Sijie Yu Yuhan Zhang Chongkai Shen Fei Shao Source Type: research
Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis
CONCLUSIONS: This meta-analysis indicates that most pharmacotherapies decreased the frequency of binge-eating and vomiting episodes, body weight, and depressive symptoms in BN patients, but the efficacy was not significant. In each drug the efficacy is different, treating different aspects, different symptoms to improve the clinical performance of bulimia nervosa.PMID:38042827 | PMC:PMC10693702 | DOI:10.1186/s40360-023-00713-7 (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - December 2, 2023 Category: Drugs & Pharmacology Authors: Sijie Yu Yuhan Zhang Chongkai Shen Fei Shao Source Type: research
Pharmacological treatments in panic disorder in adults: a network meta-analysis
CONCLUSIONS: In terms of efficacy, SSRIs, SNRIs (venlafaxine), TCAs, MAOIs and BDZs may be effective, with little difference between classes. However, it is important to note that the reliability of these findings may be limited due to the overall low quality of the studies, with all having unclear or high risk of bias across multiple domains. Within classes, some differences emerged. For example, amongst the SSRIs paroxetine and fluoxetine seem to have stronger evidence of efficacy than sertraline. Benzodiazepines appear to have a small but significant advantage in terms of tolerability (incidence of dropouts) over other ...
Source: Cochrane Database of Systematic Reviews - November 28, 2023 Category: General Medicine Authors: Giuseppe Guaiana Nicholas Meader Corrado Barbui Simon Jc Davies Toshi A Furukawa Hissei Imai Sofia Dias Deborah M Caldwell Markus Koesters Aran Tajika Irene Bighelli Alessandro Pompoli Andrea Cipriani Sarah Dawson Lindsay Robertson Source Type: research
Pharmacological treatments in panic disorder in adults: a network meta-analysis
CONCLUSIONS: In terms of efficacy, SSRIs, SNRIs (venlafaxine), TCAs, MAOIs and BDZs may be effective, with little difference between classes. However, it is important to note that the reliability of these findings may be limited due to the overall low quality of the studies, with all having unclear or high risk of bias across multiple domains. Within classes, some differences emerged. For example, amongst the SSRIs paroxetine and fluoxetine seem to have stronger evidence of efficacy than sertraline. Benzodiazepines appear to have a small but significant advantage in terms of tolerability (incidence of dropouts) over other ...
Source: Cochrane Database of Systematic Reviews - November 28, 2023 Category: General Medicine Authors: Giuseppe Guaiana Nicholas Meader Corrado Barbui Simon Jc Davies Toshi A Furukawa Hissei Imai Sofia Dias Deborah M Caldwell Markus Koesters Aran Tajika Irene Bighelli Alessandro Pompoli Andrea Cipriani Sarah Dawson Lindsay Robertson Source Type: research
Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report
Conclusions: Machine learning can predict normative QoL after antidepressant treatment with similar performance to that of prior work predicting depressive symptom response and remission. These results suggest that QoL outcomes in MDD patients can be predicted with simple patient-rated measures and provide a foundation to further improve performance and demonstrate clinical utility.Trial Registration: ClinicalTrials.gov identifiers NCT00021528 and NCT01655706.PMID:37967350 | DOI:10.4088/JCP.23m14864 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - November 15, 2023 Category: Psychiatry Authors: Tejas Phaterpekar John-Jose Nunez Emma Morton Yang S Liu Bo Cao Benicio N Frey Roumen V Milev Daniel J M üller Susan Rotzinger Claudio N Soares Valerie H Taylor Rudolf Uher Sidney H Kennedy Raymond W Lam Source Type: research
